News

1 2 3 4 5 6 7 12 18 23
NEWS

SOTIO to Present New Data on the IL-15 superagonist SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

  • SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors.

SOTIO, a clinical stage immuno-oncology company, and Cytune Pharma, both owned by PPF Group, today announced that they will present a late breaking poster highlighting new clinical data on SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting to be held virtually November 9-14, 2020. SO-C101 is an IL-15 superagonist currently being investigated in a Phase 1 trial for the treatment of advanced solid tumors. Two additional posters will also be presented summarizing the latest preclinical data on SO-C101. 

NEWS

SOTIO to Present at BIO-Europe Digital 2020

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that Jens Hennecke, chief business officer of SOTIO, is presenting on our lead programs at BIO-Europe Digital being held on October 26-29, 2020. The presentation will be made available on demand on the Bio Europe website and accessible to attendees registered for the event.

NEWS

SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics

  • SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts. 
  • Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies. 
  • Lead program expected to initiate first clinical studies in 2021.
  • Rights to BOXR platform acquired for total of $11.5 million, including $8.1 million upfront and potential $3.4 million in milestones.

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that it has acquired the rights to Unum Therapeutics’ (Nasdaq: UMRX) BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors. The proprietary Bolt-on Chimeric Receptor technology incorporates novel transgenes to enhance T cell function in the solid tumor microenvironment.